Kantaro’s COVID-SeroKlir Antibody Test Named as a Finalist for Fast Company’s 2021 World Changing Ideas Awards

Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE: RENX / NASDAQ: RNLX), announced today that COVID-SeroKlir, its semi-quantitative SARS-CoV-2 IgG antibody test, was named as a finalist in the Pandemic Response category of the 2021 World Changing Ideas Awards.

COVID-SeroKlir measures the presence and precise level of IgG antibodies against the receptor-binding domain and the full-length spike protein — the same type of antibodies produced as part of the immune response to COVID-19 virus exposure or generated by a vaccine. Unlike most other antibody tests, COVID-SeroKlir reports a numerical answer, not just a yes/no qualitative result. It is a high performing test that can be used in any authorized clinical testing laboratory without the need for proprietary equipment.

“Our focus from the beginning of COVID-19 was to make the Kantaro antibody test broadly accessible worldwide to help determine public health strategies and inform healthcare decision making,” said Sara Barrington, chief commercial officer, Kantaro. “We are honored to be recognized by Fast Company for our Pandemic Response efforts and continue to pursue our goal in helping the world emerge from the pandemic.”

Kantaro achieved a variety of milestones since the company’s launch in May 2020, including launching COVID-SeroIndex for research use only; a commercial partnership with Bio-Techne Corporation (NASDAQ: TECH) to manufacture, sell and distribute the Kantaro tests at scale; CE marking for COVID-SeroKlir and COVID-SeroIndex; and Emergency Use Authorization by the FDA for COVID-SeroKlir. Through strategic partnerships, Kantaro also established a global presence in the UK, Europe and South America.

World Changing Ideas is one of Fast Company’s major annual awards programs and is focused on social good, seeking to elevate finished products and brave concepts that make the world better. A panel of judges from across sectors choose winners, finalists, and honorable mentions from a pool of more than 4,000 entries based on feasibility and the potential for impact. With the goals of awarding ingenuity and fostering innovation, Fast Company draws attention to ideas with great potential and helps them expand their reach to inspire more people to start working on solving the problems that affect us all.

About Kantaro Biosciences
Kantaro Biosciences, a joint venture between the Mount Sinai Health System and RenalytixAI, is dedicated to ensuring that high-quality diagnostic tests for critical health challenges are accessible. The company provides rigorous, results-driven and reproducible diagnostics to advance the care and well-being of people, communities and society. Kantaro specializes in the rapid scale-up of groundbreaking diagnostic innovations and the creation of partnerships to bring these crucial technologies to market. Kantaro was named one of the World’s Most Innovative Companies by Fast Company in 2021. For more information, visit www.Kantarobio.com and follow Kantaro on Twitter @kantarobio.

About Fast Company
Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. The editor-in-chief is Stephanie Mehta. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with our sister publication Inc., and can be found online at www.fastcompany.com.